The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

Alzheimer's and Dementia

Volumn 11, Issue 7, 2015, Pages 757-771

  Jagust, William J ^a   Landau, Susan M ^a   Koeppe, Robert A ^b   Reiman, Eric M ^c   Chen, Kewei ^c   Mathis, Chester A ^d   Price, Julie C ^d   Foster, Norman L ^e   Wang, Angela Y ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Fluorodeoxyglucose; Mild cognitive impairment; PET imaging

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; COGNITION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DATA ANALYSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PERFUSION; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC IMAGING; GENETICS; LONGITUDINAL STUDY; THREE DIMENSIONAL IMAGING;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGING, THREE-DIMENSIONAL; LONGITUDINAL STUDIES; POSITRON-EMISSION TOMOGRAPHY;

EID: 84937571516     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.05.001     Document Type: Review

References (49)

1. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, C.A. Mathis, and et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 2010 221 229
2. S. Salloway, R. Sperling, N.C. Fox, K. Blennow, W. Klunk, M. Raskind, and et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
3. R.A. Sperling, D.M. Rentz, K.A. Johnson, J. Karlawish, M. Donohue, D.P. Salmon, and et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6 2014 228fs13
4. J. Talairach, and P. Tournoux Co-planar stereotaxic atlas of the human brain 1988 Thieme New York
5. S.M. Landau, M.A. Mintun, A.D. Joshi, R.A. Koeppe, R.C. Petersen, P.S. Aisen, and et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol 72 2012 578 586
6. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, and et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
7. C.R. Jack Jr., H.J. Wiste, T.G. Lesnick, S.D. Weigand, D.S. Knopman, P. Vemuri, and et al. Brain beta-amyloid load approaches a plateau Neurology 80 2013 890 896
8. S.M. Landau, A. Fero, S.L. Baker, R. Koeppe, M. Mintun, K. Chen, and et al. Measurement of longitudinal beta-amyloid change with 18f-florbetapir pet and standardized uptake value ratios J Nucl Med 56 2015 567 574
9. K. Chen, A. Roontiva, P. Thiyyagura, W. Lee, X. Liu, N. Ayutyanont, and et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region J Nucl Med 56 2015 560 566
10. M. Brendel, M. Hogenauer, A. Delker, J. Sauerbeck, P. Bartenstein, J. Seibyl, and et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction Neuroimage 108 2015 450 459
11. J.C. Price, W.E. Klunk, B.J. Lopresti, X. Lu, J.A. Hoge, S.K. Ziolko, and et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B J Cereb Blood Flow Metab 25 2005 1528 1547
12. W.E. Klunk, R.A. Koeppe, J.C. Price, T.L. Benzinger, M.D. Devous Sr., W.J. Jagust, and et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET Alzheimers Dement 11 2015 1 15.e4
13. S.M. Landau, M. Lu, A.D. Joshi, M. Pontecorvo, M.A. Mintun, J.Q. Trojanowski, and et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid Ann Neurol 74 2013 826 836
14. N. Mattsson, P.S. Insel, M. Donohue, S. Landau, W.J. Jagust, L.M. Shaw, and et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease Brain 138 2015 772 783
15. S.M. Landau, B.A. Thomas, L. Thurfjell, M. Schmidt, R. Margolin, M. Mintun, and et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers Eur J Nucl Med Mol Imaging 41 2014 1398 1407
16. R. Vandenberghe, K. Van Laere, A. Ivanoiu, E. Salmon, C. Bastin, E. Triau, and et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann Neurol 68 2010 319 329
17. V.L. Villemagne, R.S. Mulligan, S. Pejoska, K. Ong, G. Jones, G. O'Keefe, and et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease Eur J Nucl Med Mol Imaging 39 2012 983 989
18. R.Y. Lo, A.E. Hubbard, L.M. Shaw, J.Q. Trojanowski, R.C. Petersen, P.S. Aisen, and et al. Longitudinal change of biomarkers in cognitive decline Arch Neurol 68 2011 1257 1266
19. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, P.S. Aisen, and et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
20. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, and et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
21. R.Y. Lo, W.J. Jagust Alzheimer's Disease Neuroimaging Initiative Vascular burden and Alzheimer disease pathologic progression Neurology 79 2012 1349 1355
22. T.J. Haight, S.M. Landau, O. Carmichael, C. Schwarz, C. DeCarli, W.J. Jagust, and et al. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism JAMA Neurol 70 2013 1039 1045
23. J.B. Langbaum, K. Chen, W. Lee, C. Reschke, D. Bandy, A.S. Fleisher, and et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Neuroimage 45 2009 1107 1116
24. K. Chen, N. Ayutyanont, J.B. Langbaum, A.S. Fleisher, C. Reschke, W. Lee, and et al. Characterizing Alzheimer's disease using a hypometabolic convergence index Neuroimage 56 2011 52 60
25. K. Chen, J.B. Langbaum, A.S. Fleisher, N. Ayutyanont, C. Reschke, W. Lee, and et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative Neuroimage 51 2010 654 664
26. L.A. Beckett, D.J. Harvey, A. Gamst, M. Donohue, J. Kornak, H. Zhang, and et al. The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes Alzheimers Dement 6 2010 257 264
27. A. Caroli, A. Prestia, K. Chen, N. Ayutyanont, S.M. Landau, C.M. Madison, and et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison J Nucl Med 53 2012 592 600
28. F. Schraml, K. Chen, N. Ayutyanont, R. Auttawut, J.B. Langbaum, W. Lee, and et al. Association between an Alzheimer's disease-related index and gene dose PLoS One 8 2013 e67163
29. A.S. Fleisher, K. Chen, Y.T. Quiroz, L.J. Jakimovich, M. Gutierrez Gomez, C.M. Langois, and et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study JAMA Neurol 72 2015 316 324
30. H.D. Protas, K. Chen, J.B. Langbaum, A.S. Fleisher, G.E. Alexander, W. Lee, and et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease JAMA Neurol 70 2013 320 325
31. J.B. Toledo, N.J. Cairns, X. Da, K. Chen, D. Carter, A. Fleisher, and et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings Acta Neuropathol Commun 1 2013 65
32. J.B. Toledo, M.W. Weiner, D.A. Wolk, X. Da, K. Chen, S.E. Arnold, and et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition Acta Neuropathol Commun 2 2014 26
33. J. Shi, C.M. Stonnington, P.M. Thompson, K. Chen, B. Gutman, C. Reschke, and et al. Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry Neuroimage 104 2015 1 20
34. X. Wu, J. Li, N. Ayutyanont, H. Protas, W. Jagust, A. Fleisher, and et al. The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease IEEE/ACM Trans Comput Biol Bioinform 10 2013 173 180
35. S. Tzimopoulou, V.J. Cunningham, T.E. Nichols, G. Searle, N.P. Bird, P. Mistry, and et al. A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease J Alzheimers Dis 22 2010 1241 1256
36. T. Wang, Q. Huang, E.M. Reiman, K. Chen, X. Li, G. Li, and et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial J Clin Psychopharmacol 33 2013 636 642
37. J.B. Langbaum, A.S. Fleisher, K. Chen, N. Ayutyanont, F. Lopera, Y.T. Quiroz, and et al. Ushering in the study and treatment of preclinical Alzheimer disease Nat Rev Neurol 9 2013 371 381
38. E.M. Reiman, J.B. Langbaum, and P.N. Tariot Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible Biomark Med 4 2010 3 14
39. S. Minoshima, R.A. Koeppe, K.A. Frey, and D.E. Kuhl Anatomic standardization: linear scaling and nonlinear warping of functional brain images J Nucl Med 35 1994 1528 1537
40. A.H. Rostomian, C. Madison, G.D. Rabinovici, and W.J. Jagust Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients J Nucl Med 52 2011 173 179
41. I.T. Hsiao, C.C. Huang, C.J. Hsieh, W.C. Hsu, S.P. Wey, T.C. Yen, and et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies Eur J Nucl Med Mol Imaging 39 2012 613 620
42. J. Ashburner, and K.J. Friston Nonlinear spatial normalization using basis functions Hum Brain Mapp 7 1999 254 266
43. S.M. Landau, C. Breault, A.D. Joshi, M. Pontecorvo, C.A. Mathis, W.J. Jagust, and et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods J Nucl Med 54 2013 70 77
44. D.T. Chien, S. Bahri, A.K. Szardenings, J.C. Walsh, F. Mu, M.Y. Su, and et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807 J Alzheimers Dis 34 2013 457 468
45. M. Maruyama, H. Shimada, T. Suhara, H. Shinotoh, B. Ji, J. Maeda, and et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls Neuron 79 2013 1094 1108
46. N. Okamura, S. Furumoto, M.T. Fodero-Tavoletti, R.S. Mulligan, R. Harada, P. Yates, and et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET Brain 137 2014 1762 1771
47. V.L. Villemagne, M.T. Fodero-Tavoletti, C.L. Masters, and C.C. Rowe Tau imaging: early progress and future directions Lancet Neurol 14 2015 114 124
48. R. Ossenkoppele, D.R. Schonhaut, S.L. Baker, J.P. O'Neil, M. Janabi, P.M. Ghosh, and et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy Ann Neurol 77 2015 338 342
49. C.R. Jack Jr., D.S. Knopman, S.D. Weigand, H.J. Wiste, P. Vemuri, V. Lowe, and et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease Ann Neurol 71 2012 765 775